Compounders get a pass on BPC-157, TB-500 and four others if they meet sourcing and reporting rules. The Alliance for Pharmacy Compounding cheers it, while Public Citizen calls it reckless.
Recap by typeshit. Full story at Fierce Pharma.
AP sources say FDA scientists opposed the HHS draft telling the agency not to act against pharmacies compounding six wellness peptides. Comments are open for two weeks.
Law firm Frier Levitt reads the rule as single-ingredient only, so the popular blend stays out. Public Citizen and ex-FDA official Janet Woodcock voice safety concerns.
Six peptides can now be compounded under strict conditions, but HHS itself says that proves nothing on safety, and research-use-only sellers stay outside the policy.
Hims & Hers and a peptide academy met White House reviewers before release, and the Partnership for Safe Medicines has petitioned the FDA to block it.
The posters cover baseline traits in the phase 3 VANQUISH-2 trial and cardiometabolic measures from the phase 2 VENTURE study, November 14 to 17.
Healio
At a Boston masterclass, the Harvard obesity doctor said GLP-1s should be treated as indefinite care, since weight returns when they stop.
Loading…